$INCY

Issa Mohamed Khairie sold $126K of INCY

Issa Mohamed Khairie (EVP, Head of U.S. Commercial) sold 1,093 shares of INCYTE CORP (INCY) at $115.01 ($0.13M total) on 2026-07-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Issa Mohamed Khairie
Published Jul 20, 2026, 8:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 20, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The disclosure updates insider trading records but does not introduce new information about Incyte’s business performance or outlook.

02

Market read

Traders may note the insider sale for sentiment, but the 10b5-1 structure reduces interpretive weight.

03

What to watch

The article does not state whether other insiders sold/bought around the same period, nor does it quantify total insider activity beyond this one transaction.

Relevance 3/10Novelty 3/10Timing: filed 2026-07-20 after-hours, covering a sale dated 2026-07-16

Background

The article is an SEC Form 4 insider transaction for Incyte, reported by an EVP in the U.S. Commercial organization.

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows EVP Issa Mohamed Khairie sold 1,093 shares on 2026-07-16 under a pre-arranged 10b5-1 plan.

Expected impact

Limited near-term impact; any effect is likely sentiment-only and short-lived.

Evidence & confidence

The filing is a Form 4 open-market sale with a stated 10b5-1 plan, and it provides no new company fundamentals, guidance, or regulatory/contract developments.

Market effects

No direct read-through to biotech sector fundamentals from a single 10b5-1 insider sale.

None.

None.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • INCY

    Incyte Corporation, the company whose insider transaction is disclosed.

  • Issa Mohamed Khairie

    EVP, Head of U.S. Commercial, who executed an open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MIRMHighAI 9/10

Mirum wins FDA Atebrioz approval for FOP patients 12+

Mirum Pharmaceuticals (MIRM) received FDA approval for Atebrioz to treat FOP in patients aged 12+. The drug, developed by Incyte (INCY), showed a reduction in new bone-lesion volume in a 63-patient study. U.S. availability is expected in October, with a patient support program in place. Mirum shares closed at $89.70, Incyte at $123.89 on Friday.

$MIRMHighAI 9/10

Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced FDA approval of Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12+. The once-daily oral ALK2 inhibitor showed efficacy in reducing heterotopic ossification in clinical trials. Atebrioz is expected to be available in the U.S. in October, with eligible patients paying as little as $0 per month through Mirum's patient support program.

$INCYHighAI 8/10

EMA OKs Two Options for Refractory Inflammatory Conditions

The EMA's CHMP approved Povofortay (Incyte) for marketing to treat moderate to severe hidradenitis suppurativa (HS) in adults who failed anti-TNF therapy. It is the first oral option for HS, reducing pain and lesions. Cosentyx (Novartis) gained a new indication for polymyalgia rheumatica (PMR) in adults unresponsive to glucocorticoids. Both drugs showed efficacy in clinical trials.